V Square Quantitative Management LLC Acquires 248 Shares of Insmed Incorporated (NASDAQ:INSM)

V Square Quantitative Management LLC boosted its holdings in Insmed Incorporated (NASDAQ:INSM) by 60.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 659 shares of the biopharmaceutical company’s stock after acquiring an additional 248 shares during the quarter. V Square Quantitative Management LLC’s holdings in Insmed were worth $45,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Values First Advisors Inc. lifted its position in shares of Insmed by 4.4% during the 4th quarter. Values First Advisors Inc. now owns 5,199 shares of the biopharmaceutical company’s stock worth $359,000 after buying an additional 221 shares during the period. Legato Capital Management LLC increased its holdings in shares of Insmed by 2.2% during the fourth quarter. Legato Capital Management LLC now owns 36,871 shares of the biopharmaceutical company’s stock worth $2,546,000 after buying an additional 792 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of Insmed by 8.4% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 423,094 shares of the biopharmaceutical company’s stock worth $29,590,000 after acquiring an additional 32,960 shares in the last quarter. Financial Advocates Investment Management acquired a new position in Insmed in the fourth quarter worth $335,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Insmed by 3.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,401 shares of the biopharmaceutical company’s stock valued at $446,000 after buying an additional 186 shares in the last quarter.

Insider Activity at Insmed

In related news, insider Martina M.D. Flammer sold 6,172 shares of Insmed stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $63.64, for a total value of $392,786.08. Following the transaction, the insider now directly owns 101,549 shares of the company’s stock, valued at $6,462,578.36. This trade represents a 5.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO William Lewis sold 18,750 shares of the business’s stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $69.91, for a total value of $1,310,812.50. Following the transaction, the chief executive officer now directly owns 384,960 shares of the company’s stock, valued at $26,912,553.60. This trade represents a 4.64 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 495,135 shares of company stock valued at $38,409,713. Insiders own 4.60% of the company’s stock.

Insmed Stock Up 0.8 %

Shares of Insmed stock opened at $79.31 on Tuesday. The firm has a market cap of $14.19 billion, a PE ratio of -14.29 and a beta of 1.11. The business’s 50 day simple moving average is $73.51 and its 200 day simple moving average is $73.31. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $82.04.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Morgan Stanley upped their target price on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Guggenheim increased their price objective on shares of Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a report on Friday, February 7th. JPMorgan Chase & Co. lifted their target price on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Friday, February 7th. Stifel Nicolaus increased their target price on Insmed from $88.00 to $97.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. Finally, HC Wainwright restated a “buy” rating and set a $90.00 price objective on shares of Insmed in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, Insmed has a consensus rating of “Moderate Buy” and an average target price of $88.71.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.